open access

Vol 63, No 1 (2013)
Research paper (original)
Published online: 2013-03-08
Get Citation

The prognostic value of DNA microsatellite instability analysis in breast cancer

Artur Bocian, Jolanta Szkudlarek, Jacek Bartkowiak
Nowotwory. Journal of Oncology 2013;63(1):21-27.

open access

Vol 63, No 1 (2013)
Original article
Published online: 2013-03-08

Abstract

Introduction. Breast carcinoma is one of the most common malignancies in women, and its carcinogenesis etiology
is still unknown. Loss of MMR function prevents the correction of replicative errors leading to instability of the genome,
and can be detected by polymorphisms in micro satellites (1–6 nucleotide repeat sequences). This is known
as microsatellite instability (MSI), and is a hallmark of MMR dysfunction and can thus be used as a marker of MMR
dysfunction in colorectal and other malignancies.

Material and methods. We studied the presence of MSI in 81 invasive breast cancers and evaluated its relationship
with patient age, tumor size, tumor type, lymph node metastasis, liver metastasis, brain metastasis, local recurrence,
and other. Microsatellite analysis was performed using 10 markers selected for sensitive detection of microsatellite
instability in breast cancer.

Results. MSI was detected in 40 of 81 cases (49.4%), where MSI-H was in 15 cases (18.5%) and MSI-L was in 25 cases
(30.9%). A statistically significant correlation was observed between MSI and liver metastasis and brain metastasis. We
also found a correlation (not statistically significant) between MSI-H and lobular carcinoma.

Conclusion. The analyzes performed showed that the presence of MSI in breast cancer was associated with shorter
survival and was more aggressive when metastases to the liver and brain were present.

Abstract

Introduction. Breast carcinoma is one of the most common malignancies in women, and its carcinogenesis etiology
is still unknown. Loss of MMR function prevents the correction of replicative errors leading to instability of the genome,
and can be detected by polymorphisms in micro satellites (1–6 nucleotide repeat sequences). This is known
as microsatellite instability (MSI), and is a hallmark of MMR dysfunction and can thus be used as a marker of MMR
dysfunction in colorectal and other malignancies.

Material and methods. We studied the presence of MSI in 81 invasive breast cancers and evaluated its relationship
with patient age, tumor size, tumor type, lymph node metastasis, liver metastasis, brain metastasis, local recurrence,
and other. Microsatellite analysis was performed using 10 markers selected for sensitive detection of microsatellite
instability in breast cancer.

Results. MSI was detected in 40 of 81 cases (49.4%), where MSI-H was in 15 cases (18.5%) and MSI-L was in 25 cases
(30.9%). A statistically significant correlation was observed between MSI and liver metastasis and brain metastasis. We
also found a correlation (not statistically significant) between MSI-H and lobular carcinoma.

Conclusion. The analyzes performed showed that the presence of MSI in breast cancer was associated with shorter
survival and was more aggressive when metastases to the liver and brain were present.
Get Citation
About this article
Title

The prognostic value of DNA microsatellite instability analysis in breast cancer

Journal

Nowotwory. Journal of Oncology

Issue

Vol 63, No 1 (2013)

Article type

Research paper (original)

Pages

21-27

Published online

2013-03-08

Page views

737

Article views/downloads

6910

Bibliographic record

Nowotwory. Journal of Oncology 2013;63(1):21-27.

Authors

Artur Bocian
Jolanta Szkudlarek
Jacek Bartkowiak

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl